Sorry, you need to enable JavaScript to visit this website.
  • share

Looking for Acute
For adults and children 12 years of age and older who have taken corticosteroids and they did not work well enough

Support and Resources for Patients Taking Jakafi®

IncyteCARES for Jakafi Patient Support Program

At IncyteCARES for Jakafi, our team can help with access and support for your treatment.


Coverage Verification

We can check with a patient’s insurance plan about their coverage for Jakafi and any out-of-pocket costs required.

Graphic of a hand and Rx

Insurance Assistance

We can help patients understand how their insurance plan works. We can also offer information about prior authorization requirements and appealing insurance denials or restrictions.

Graphic of a mailbox

Delivery Coordination

We can arrange to have the patient’s prescription for Jakafi filled by an approved specialty pharmacy and delivered directly to either the patient’s home or Healthcare Professional’s office.

Graphic of a copay assistance card

Savings Program

For patients with commercial prescription drug coverage—eligible patients pay as little as $0 per month, subject to certain limits.*

Graphic of hand offering a prescription

Patient Assistance Program (PAP)

Free product is offered to eligible patients who are uninsured or underinsured for Jakafi.

Graphic of a clock

Temporary Coverage

For insurance coverage delays, eligible patients can receive a free short-term supply of Jakafi.

Graphic of a book

Patient Education and Support

Through our call center, IncyteCARES for Jakafi representatives can answer patient and caregiver questions about graft-versus-host disease and Jakafi.

Graphic of hands in the shape of a heart

Connection to Other Support Services

For patients who need additional support beyond what we can provide directly, IncyteCARES for Jakafi can offer information about other independent organizations that may be able to help.

Graphic of a copay assistance card

*Amount of savings for the purchase of Jakafi will not exceed $11,977 per month and $25,000 per year. Uninsured, cash-paying patients are not eligible. Not valid for patients insured through Medicare Part D, Medicare Advantage, Medicaid, and TRICARE or any state medical or pharmaceutical assistance program. Valid prescription for Jakafi for an FDA-approved indication or compendia-recognized use is required. Please see full criteria for eligibility or call IncyteCARES for Jakafi at 1-855-452-5234. Update effective as of July 13, 2021.

Terms and conditions apply. Terms of these programs may change at any time. No purchase contingencies or other obligations apply.

How to Enroll in IncyteCARES for Jakafi

Once you’ve been prescribed Jakafi, you can either:
  • Call IncyteCARES for Jakafi to get started at 1-855-452-5234 


  • Ask your prescribing Healthcare Professional to enroll you
Note that not all patients who have been prescribed Jakafi are eligible to enroll in IncyteCARES for Jakafi or to receive all services we provide.

Visit to Learn More

Graphic of a person wearing headphones
Connect with IncyteCARES for Jakafi today!
Visit: or call: 1-855-452-5234
Monday through Friday, 8 AM – 8 PM ET.







Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is used to treat adults with certain types of myelofibrosis.

Jakafi is used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

Jakafi is also used to treat adults and children 12 years of age and older with chronic GVHD who have taken one or two types of treatments and they did not work well enough.

Important Safety Information

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Cancer: Some people have had certain types of non-melanoma skin cancers during treatment with Jakafi. Your healthcare provider will regularly check your skin during your treatment with Jakafi. Tell your healthcare provider if you develop any new or changing skin lesions during treatment with Jakafi.

Increases in cholesterol: You may have changes in your blood cholesterol levels during treatment with Jakafi. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking Jakafi, and as needed.

Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis: Get emergency help right away if you have any symptoms of a heart attack or stroke while taking Jakafi, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back, severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw, pain or discomfort in your arms, back, neck, jaw, or stomach, shortness of breath with or without chest discomfort, breaking out in a cold sweat, nausea or vomiting, feeling lightheaded, weakness in one part or on one side of your body, slurred speech.

Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with Jakafi, including: swelling, pain, or tenderness in one or both legs, sudden, unexplained chest or upper back pain, shortness of breath or difficulty breathing.

Possible increased risk of new (secondary) cancers: People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers.

The most common side effects of Jakafi include: for certain types of myelofibrosis (MF) and polycythemia vera (PV) – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; for acute GVHD – low platelet counts, low red or white blood cell counts, infections, and swelling; and for chronic GVHD – low red blood cell or platelet counts and infections including viral infections.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Call your doctor for medical advice about side effects.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had low white or red blood cell counts, have or had tuberculosis (TB) or have been in close contact with someone who has TB, had shingles (herpes zoster), have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had cancer, are a current or past smoker, had a blood clot, heart attack, other heart problems or stroke, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.